Dr. Chipollini is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3838 N Campbell Ave
Tucson, AZ 85719Phone+1 520-694-4032- Is this information wrong?
Summary
- Juan Chipollini, MD, FACS is an urologic oncologist and associate professor in the Department of Urology. He completed residency at the University of Miami Miller School of Medicine and went to H. Lee Moffitt Cancer Center for a Society of Urologic Oncology fellowship where he specialized in the management of urologic malignancies using both complex open and minimally-invasive surgery. Dr. Chipollini is board-certified by the American Board of Urology. He has research interests involving novel biomarkers in urothelial carcinoma. He also studies heath disparities in the treatment of urologic cancer patients. He has an active surgical practice and is principal investigator in several clinical trials at the University of Arizona.
Education & Training
- H. Lee Moffitt Cancer Center and Research InstituteFellowship, Urologic Surgical Oncology, 2016 - 2018
- University of Miami/Jackson Health SystemResidency, Urology, 2012 - 2016
- University of Miami/Jackson Health SystemResidency, Surgery, 2011 - 2012
- University of Arkansas For Medical Sciences College of MedicineClass of 2011
Certifications & Licensure
- AZ State Medical License 2017 - 2025
- American Board of Urology Urology
Awards, Honors, & Recognition
- Inductee Alpha Omega Alpha Honor Medical Society, 2011
Clinical Trials
- Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer Start of enrollment: 2018 Sep 24
- Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland Start of enrollment: 2021 Jul 23
- Study to Determine Possible Effects of Apalutamide on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer Start of enrollment: 2024 Jun 15
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Neighborhood social vulnerability and disparities in time to kidney cancer surgical treatment and survival in Arizona.Celina I Valencia, Patrick Wightman, Kristin E Morrill, Chiu-Hsieh Hsu, Hina Arif-Tiwari, Eric Kauffman, Francine C Gachupin, Juan Chipollini, Benjamin R Lee, David O ...> ;Cancer Medicine. 2024 Feb 1
- Current Landscape of Immune Checkpoint Inhibitors for Metastatic Urothelial Carcinoma: Is There a Role for Additional T-Cell Blockade?Ogbuji, V., Paster, I., Recio-Boiles, A., Carew, J., Nawrocki, S., Chipollini, J.> ;Cancers. 2023 Dec 27
- Analysis of prognostic factors in patients diagnosed with bladder cancer complicated by hemorrhage treated by drug-eluting bead embolization.Peng, J., Weng, Z., Zhang, C., Zhou, G., Lin, Y., Kołat, D., Wu, W., Chipollini, J.> ;Translational Andrology and Urology. 2023 Nov 30
- Join now to see all
Press Mentions
- Cytoreductive Surgery May Have a Role in Treating Metastatic UTUCFebruary 1st, 2021
- Identifying an Optimal Lymph Node Yield for Penile Squamous Cell Carcinoma: Prognostic Impact of Surgical Dissection - Beyond the AbstractNovember 25th, 2019
- Mutational Characteristics of Chemotherapy-Treated Bladder Urothelial NeoplasmsDecember 23rd, 2016
Professional Memberships
- Member
- Member
- Fellow
Hospital Affiliations
- Banner - University Medical Center SouthTucson, Arizona
- Banner - University Medical Center TucsonTucson, Arizona
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: